CN103965362A - 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体 - Google Patents
一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体 Download PDFInfo
- Publication number
- CN103965362A CN103965362A CN201310046965.XA CN201310046965A CN103965362A CN 103965362 A CN103965362 A CN 103965362A CN 201310046965 A CN201310046965 A CN 201310046965A CN 103965362 A CN103965362 A CN 103965362A
- Authority
- CN
- China
- Prior art keywords
- cell
- factor
- tumor
- fusion rotein
- peptide section
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 55
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 44
- 102000019034 Chemokines Human genes 0.000 title abstract description 8
- 108010012236 Chemokines Proteins 0.000 title abstract description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 85
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 30
- 230000005012 migration Effects 0.000 claims abstract description 17
- 238000013508 migration Methods 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 51
- 230000004927 fusion Effects 0.000 claims description 37
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 28
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 28
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 28
- 239000013598 vector Substances 0.000 claims description 21
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 20
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 238000012239 gene modification Methods 0.000 claims description 11
- 230000005017 genetic modification Effects 0.000 claims description 11
- 235000013617 genetically modified food Nutrition 0.000 claims description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 9
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 4
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 102000013275 Somatomedins Human genes 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 4
- 230000007954 hypoxia Effects 0.000 claims description 4
- 230000001177 retroviral effect Effects 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 102000002262 Thromboplastin Human genes 0.000 claims description 3
- 108010000499 Thromboplastin Proteins 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 238000009098 adjuvant therapy Methods 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 3
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 201000007487 gallbladder carcinoma Diseases 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- -1 pHGF Proteins 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 201000000498 stomach carcinoma Diseases 0.000 claims description 3
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000005611 electricity Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 210000003162 effector t lymphocyte Anatomy 0.000 abstract description 3
- 230000009809 T cell chemotaxis Effects 0.000 abstract description 2
- 238000011467 adoptive cell therapy Methods 0.000 abstract description 2
- 238000012546 transfer Methods 0.000 abstract description 2
- 108010033276 Peptide Fragments Proteins 0.000 abstract 4
- 102000007079 Peptide Fragments Human genes 0.000 abstract 4
- 239000012528 membrane Substances 0.000 abstract 1
- 210000002536 stromal cell Anatomy 0.000 abstract 1
- 230000005909 tumor killing Effects 0.000 abstract 1
- 102000009410 Chemokine receptor Human genes 0.000 description 23
- 108050000299 Chemokine receptor Proteins 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 17
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 11
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 11
- 230000003399 chemotactic effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 5
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 4
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 4
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 4
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 4
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 4
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 4
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000005674 CCR Receptors Human genes 0.000 description 2
- 108010059983 CCR Receptors Proteins 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000034196 cell chemotaxis Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000004862 vasculogenesis Effects 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000018361 Contactin Human genes 0.000 description 1
- 108060003955 Contactin Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102100030304 Platelet factor 4 Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 101150030763 Vegfa gene Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310046965.XA CN103965362B (zh) | 2013-02-06 | 2013-02-06 | 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310046965.XA CN103965362B (zh) | 2013-02-06 | 2013-02-06 | 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103965362A true CN103965362A (zh) | 2014-08-06 |
CN103965362B CN103965362B (zh) | 2019-02-01 |
Family
ID=51235405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310046965.XA Active CN103965362B (zh) | 2013-02-06 | 2013-02-06 | 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103965362B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107106671A (zh) * | 2015-04-03 | 2017-08-29 | 优瑞科生物技术公司 | 靶向afp肽/mhc复合体的构建体及其用途 |
CN110117329A (zh) * | 2019-04-03 | 2019-08-13 | 河北浓孚雨生物科技有限公司 | 包含趋化因子与结合伴侣的融合多肽及其用途 |
US10822389B2 (en) | 2015-10-23 | 2020-11-03 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
CN112143700A (zh) * | 2019-06-26 | 2020-12-29 | 上海细胞治疗集团有限公司 | 制备过表达外源基因的免疫效应细胞的方法 |
CN113322238A (zh) * | 2021-06-17 | 2021-08-31 | 浙江大学 | 表达趋化因子受体的具有实体肿瘤定向趋化能力的单核细胞和巨噬细胞、及其制备和应用 |
US11613573B2 (en) | 2017-04-26 | 2023-03-28 | Eureka Therapeutics, Inc. | Chimeric antibody/T-cell receptor constructs and uses thereof |
CN116789857A (zh) * | 2022-06-21 | 2023-09-22 | 上海君赛生物科技有限公司 | 基于cxcr的信号转换受体 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004113497A2 (en) * | 2003-06-09 | 2004-12-29 | University Of Florida | Gene delivery to tumors |
WO2008134879A1 (en) * | 2007-05-04 | 2008-11-13 | University Health Network | Il-12 immunotherapy for cancer |
WO2011156356A1 (en) * | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
CN102633883A (zh) * | 2012-02-24 | 2012-08-15 | 上海白泽生物科技有限公司 | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 |
-
2013
- 2013-02-06 CN CN201310046965.XA patent/CN103965362B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004113497A2 (en) * | 2003-06-09 | 2004-12-29 | University Of Florida | Gene delivery to tumors |
WO2008134879A1 (en) * | 2007-05-04 | 2008-11-13 | University Health Network | Il-12 immunotherapy for cancer |
WO2011156356A1 (en) * | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
CN102633883A (zh) * | 2012-02-24 | 2012-08-15 | 上海白泽生物科技有限公司 | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107106671A (zh) * | 2015-04-03 | 2017-08-29 | 优瑞科生物技术公司 | 靶向afp肽/mhc复合体的构建体及其用途 |
US10011658B2 (en) | 2015-04-03 | 2018-07-03 | Eureka Therapeutics, Inc. | Constructs targeting AFP peptide/MHC complexes and uses thereof |
US10822389B2 (en) | 2015-10-23 | 2020-11-03 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
US11421013B2 (en) | 2015-10-23 | 2022-08-23 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
US11976105B2 (en) | 2015-10-23 | 2024-05-07 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
US11613573B2 (en) | 2017-04-26 | 2023-03-28 | Eureka Therapeutics, Inc. | Chimeric antibody/T-cell receptor constructs and uses thereof |
US11965021B2 (en) | 2017-04-26 | 2024-04-23 | Eureka Therapeutics, Inc. | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
CN110117329A (zh) * | 2019-04-03 | 2019-08-13 | 河北浓孚雨生物科技有限公司 | 包含趋化因子与结合伴侣的融合多肽及其用途 |
CN110117329B (zh) * | 2019-04-03 | 2020-12-08 | 河北浓孚雨生物科技有限公司 | 包含趋化因子与结合伴侣的融合多肽及其用途 |
CN112143700A (zh) * | 2019-06-26 | 2020-12-29 | 上海细胞治疗集团有限公司 | 制备过表达外源基因的免疫效应细胞的方法 |
CN113322238A (zh) * | 2021-06-17 | 2021-08-31 | 浙江大学 | 表达趋化因子受体的具有实体肿瘤定向趋化能力的单核细胞和巨噬细胞、及其制备和应用 |
CN116789857A (zh) * | 2022-06-21 | 2023-09-22 | 上海君赛生物科技有限公司 | 基于cxcr的信号转换受体 |
Also Published As
Publication number | Publication date |
---|---|
CN103965362B (zh) | 2019-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103965362A (zh) | 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体 | |
CN105177031B (zh) | 嵌合抗原受体修饰的t细胞及其用途 | |
CN110041433A (zh) | 一种靶向bcma的嵌合抗原受体及其应用 | |
CN110872577A (zh) | 修饰的免疫细胞及其应用 | |
CN110615843B (zh) | 一种包含第三信号受体的嵌合抗原受体及其应用 | |
WO2022032864A1 (zh) | 一种识别Fc片段的嵌合抗原受体及其应用 | |
CN108384760A (zh) | 携带cd20/cd19双特异性嵌合抗原受体的人t淋巴细胞及制备方法和应用 | |
CN107868792B (zh) | 靶向cd123的嵌合抗原受体及其用途 | |
CN103965361A (zh) | 一种t细胞信号的嵌合分子转换器及其用途 | |
WO2022007795A1 (zh) | 一种嵌合受体及其应用 | |
CN107164338A (zh) | 一种重组溶瘤病毒及其应用 | |
US11098123B2 (en) | OCTS technology-based pancreatic cancer and malignant mesothelioma CAR-T therapeutic vector, construction method therefor, and use thereof | |
WO2020037206A4 (en) | Recombinant myxoma viruses and uses thereof | |
CN106164090B (zh) | TRAIL穿膜肽样突变体MuR6、制备方法及应用 | |
US20220242960A1 (en) | Ghr-106 chimeric antigen receptor construct and methods of making and using same | |
CN108715616A (zh) | 靶向人源化间皮素的嵌合抗原受体方法和用途 | |
CN111848818A (zh) | 一种增强型免疫细胞及其应用 | |
CN105950662B (zh) | 一种靶向cd22的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用 | |
JP2021536256A (ja) | 修飾t細胞に対する条件的活性型キメラ抗原受容体 | |
JP6929928B2 (ja) | Hla−g特異的キメラ抗原受容体、核酸、hla−g特異的キメラ抗原受容体発現プラスミド、hla−g特異的キメラ抗原受容体発現細胞及び癌治療用の医薬組成物 | |
CN110396131B (zh) | 一种ErbB2单链抗体、靶向人ErbB2的嵌合抗原受体、重组载体、重组细胞和应用 | |
CN106349391A (zh) | Hbv特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环dna及应用 | |
CN106132986B (zh) | TRAIL穿膜肽样突变体MuR5、制备方法及应用 | |
CN111732665A (zh) | 一种靶向表达癌胚抗原的细胞的嵌合抗原受体 | |
CN110564767A (zh) | 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: No. 75 A, front Yang Road, Jiading District, Shanghai Applicant after: SHANGHAI CELL THERAPY GROUP Co.,Ltd. Address before: 201805 room 602, Mo Yu Road, Anting Town, Jiading District, Shanghai, 185 Applicant before: SHANGHAI CELL THERAPY ENGINEERING TECHNOLOGY RESEARCH CENTER Co.,Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 201805 No. 1585 Garden National Road, Anting Town, Jiading District, Shanghai Patentee after: Shanghai Cell Therapy Group Co.,Ltd. Country or region after: China Address before: No. 75 A, front Yang Road, Jiading District, Shanghai Patentee before: SHANGHAI CELL THERAPY GROUP Co.,Ltd. Country or region before: China |